<DOC>
	<DOC>NCT01020123</DOC>
	<brief_summary>The primary aim is to evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in TD2M Patients</brief_summary>
	<brief_title>Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Glipizide</mesh_term>
	<criteria>female of nonchildbearing potential Treated with maximally tolerated dose of metformin (≥ 1500mg/day) for at least 10 weeks prior to enrolment. Patients with HbA1c ≥ 7.5 but ≤ 10% at enrolment visit (Visit 1) can enter cohort 1.Patients with HbA1c between &gt;10 % and &lt;12 % can enter the openlabel arm with AZD1656 (cohort 2) Significant cardiovascular event within the last 6 months prior to enrolment or heart failure New York Heart Association (NYHA) class IIIIV. Impaired renal function in terms of GFR&lt;60 ml/min, based on Modification of Diet in Renal Disease Study Group (MDRD) calculation. Use of warfarin or amiodarone within 3 months prior to enrolment (screening) and use of potent CYP450 inhibitors, eg, ketoconazole and/or macrolide antibiotics within 14 days before randomisation.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Type II Diabetes Mellitus</keyword>
	<keyword>metformin</keyword>
	<keyword>glipizide</keyword>
</DOC>